The Latest Orphan Drug Designations and the Commission Communication on Regulation (EC) 141/2000

Journal of Commercial Biotechnology - United Kingdom
doi 10.5912/jcb122
Full Text
Abstract

Available in full text

Date
Authors
Publisher

thinkBiotech, LLC

Related search

Analysis of Orphan Drug Designations and Approvals in the United States and the European Union

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Latest Updates From the Joint Commission

Pharmacy Today
2016English

The FDA's Definitions, Designations, and Drug Approvals: Too Daring?

The Lancet Haematology
Hematology
2018English

Time to Revisit the Orphan Drug Law

European Journal of Clinical Pharmacology
MedicinePharmacology
2011English

Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1995English

The Latest Information and Communication Technologies in Lis Education

2017English

The Effect of the Orphan Drug Development Support Program.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1999English

Communication-From-The-Commission-To-The-European-Parliament-And-The-Council

English

Ac3 - Discordant Designations of Breakthrough Drug Innovation: France Versus the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy